In the high-stakes world of oncology, time is the most precious commodity. For patients battling complex malignancies, the gap between the discovery of a life-saving therapy and its actual administration can be the difference between months of survival and years of remission. For over a decade, the American Society of Clinical Oncology (ASCO) sought to bridge this divide through CancerLinQ, a massive initiative designed to aggregate real-world data from oncology practices into a unified learning system.
Today, that vision has entered a new, more aggressive phase of evolution. Following its acquisition by ConcertAI in December 2023, the platform has been fundamentally rebuilt. No longer just a repository for quality reporting, CancerLinQ is being transformed into a sophisticated, AI-driven point-of-care engine that promises to reshape how oncologists manage everything from clinical trial matching to complex treatment decision-making.
The Evolution of CancerLinQ: From Compliance to Capability
To understand the magnitude of this shift, one must look at the platform’s origins. When ASCO launched CancerLinQ, its primary utility was administrative. It functioned as a software solution that enabled oncology practices to automate the tracking and reporting of ASCO quality measures—a vital service for maintaining clinical certification.
"Before we bought it, CancerLinQ largely just delivered software that automated the measurement of ASCO certification quality measures," explains Eron Kelly, CEO of ConcertAI. It was a vital tool for compliance, but it lacked the analytical horsepower to influence the actual trajectory of patient care in real-time.
The 2023 acquisition marked a strategic pivot. ConcertAI, a leader in AI-driven oncology solutions and real-world data (RWD) analytics, recognized that the vast, longitudinal datasets contained within CancerLinQ were an untapped resource. By integrating its proprietary SaaS stack and AI model architecture, ConcertAI moved the platform from a passive reporting system to an active, intelligence-gathering infrastructure.
Chronology of a Transformation
The transition from a compliance tool to an "intelligence platform" did not happen overnight. The trajectory can be mapped as follows:
- 2010s: The Foundation. ASCO establishes CancerLinQ to gather disparate electronic health record (EHR) data, creating a learning health system intended to improve the quality of cancer care through shared data.
- December 2023: The Strategic Acquisition. ConcertAI acquires CancerLinQ from ASCO, signaling a shift toward commercial-grade AI integration and a focus on research-to-care alignment.
- 2024: Infrastructure Overhaul. ConcertAI begins the intensive process of integrating its "chain of AI models" into the CancerLinQ data pipeline, focusing on structuring unstructured data (notes, pathology, and genomics).
- 2025–2026: Scaling the Intelligence. The platform begins rolling out advanced clinical decision support (CDS) tools, automated trial-matching, and longitudinal data synthesis that refreshes on a weekly basis, rather than lagging by months.
Bridging the Care-Research Divide
The central challenge in modern oncology is the rapid pace of innovation. As Dr. Shaalan Beg, Chief Medical Officer of Oncology at ConcertAI, notes, the standard of care for many cancers is evolving faster than most community practices can track.
"If you’re a pancreatic cancer patient right now and you want the best standard of care, the only way you’re going to get it is through clinical trials," Dr. Beg asserts. He points to recent ASCO data showing that new therapeutic agents can nearly double median survival in metastatic pancreatic cancer, moving the needle from six months to 12. Without a mechanism to match patients to these trials, that survival benefit remains theoretical.
ConcertAI aims to close this gap by automating the heavy lifting. By parsing EHR fields—including unstructured physician notes, pathology reports, and genomic/NGS laboratory results—the system creates a structured, queryable data model. This allows for "point-of-care synthesis," where the AI identifies potential trial candidates based on highly specific biomarkers, sparing oncologists the time-consuming process of manual chart review.
The "Lane Assist" Model: AI in the Clinical Workflow
The adoption of AI in medicine has reached a tipping point. According to a 2026 survey by the American Medical Association (AMA), 72% of physicians are now incorporating AI into their clinical practice, a significant jump from 38% in 2023. Physician awareness has mirrored this trend, climbing to 81%.
Dr. Beg uses an apt analogy to describe how these tools fit into the modern clinic: "For most of the clinical care doctors are asking for right now, it’s more like lane assist, keeping the car in its lane and giving nudges along the way."
These "nudges" represent the next generation of clinical decision support. They might inform a doctor that a colon-cancer patient is missing a specific molecular test required for targeted therapy, or flag a clinical trial that perfectly matches a patient’s current genomic profile. This is not about replacing the oncologist’s judgment; it is about augmenting their capacity in an era where the complexity of cancer care has outpaced the capabilities of any single physician.
"The era of one physician taking care of all your needs is decades over," says Dr. Beg. Modern care involves a multidisciplinary team—nurse practitioners, geneticists, dietitians, and therapists. Yet, almost no clinical program reports being "fully staffed." By acting as an efficiency layer, ConcertAI’s tools give clinicians back vital time, allowing them to manage larger patient volumes without sacrificing the quality of care.
Data Integrity: The Power of AI Chaining
The technical prowess of the new CancerLinQ lies in its "chain of AI models." As Eron Kelly explains, the platform uses a sequence of agents to parse raw medical data. One layer performs the initial abstraction—extracting the facts—while another evaluates the clinical coherence of those facts.
"We use a chain of AI models and agents to parse all that information, understand really challenging concepts like progression, or timelines within a diagnosis journey, and summarize that into a structured data model," Kelly says.
To build trust, the system employs a "layered check." If a model suggests a treatment, it cross-references the clinical logic. If the system detects a treatment that does not follow standard clinical sequences—such as a chemotherapy regimen that occurs in a sequence that contradicts established pathology—it flags the discrepancy. This reliability is critical, as clinical trust is easily lost if an AI produces "hallucinated" or clinically impossible recommendations.
Furthermore, because ConcertAI maintains the underlying pathology reports, it can perform retrospective re-evaluations. For instance, as new antibody-drug conjugates (ADCs) make it possible to treat patients who were previously classified as HER2-negative, the system can identify these patients within the existing database, essentially "rescuing" them for new, more effective treatment options.
Implications for the Future of Oncology
The implications of this technology extend far beyond individual practices. By creating a standardized, vendor-agnostic, and longitudinally updated dataset, ConcertAI is facilitating a "ground-up" approach to the War on Cancer.
While the "Moonshot" mentality—the search for a single, sweeping cure—has dominated political and public discourse for 50 years, the reality of oncology is often found in the increments. It is the refinement of a biomarker here, or the application of a better-targeted therapy there, that yields the most significant gains in survival.
"I think we should focus on ground shots first," says Dr. Beg. "Disseminating the treatments we already know work to the people who need them right now."
By embedding these intelligence tools into the daily workflow of thousands of oncologists, ConcertAI is moving the industry toward a model of precision medicine that is not just possible in elite academic centers, but accessible in community settings. As these tools continue to evolve, they will likely become as essential to the modern oncology clinic as the EHR itself—not as an autonomous replacement for human care, but as the essential navigator in an increasingly complex medical landscape.
The successful transition of CancerLinQ demonstrates that the future of cancer care does not solely reside in the laboratory, but in the intelligent, data-driven synthesis of the care we are already providing. By turning data into action, ConcertAI is ensuring that for more patients, the next breakthrough is not a hope for the future, but a standard of care for today.
About the Author
